Dr. Leonard J. Appleman
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Studies Prostate Cancer
Studies Kidney Cancer
16 reported clinical trials
36 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
MET positive
KIT positive
2Kidney Cancer
Stage IV
Stage III
FH positive
Affiliated Hospitals
Clinical Trials Leonard J. Appleman is currently running
Long-Term Safety of AAA617
for Prostate Cancer
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Recruiting3 awards Phase 4
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
More about Leonard J. Appleman
Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Leonard J. Appleman has experience with
- Abiraterone Acetate
- Prednisone
- Atezolizumab
- Cisplatin
- Tazemetostat
- Pembrolizumab
Breakdown of trials Leonard J. Appleman has run
Prostate Cancer
Kidney Cancer
Bladder Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Leonard J. Appleman specialize in?
Leonard J. Appleman focuses on Prostate Cancer and Kidney Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are MET positive.
Is Leonard J. Appleman currently recruiting for clinical trials?
Yes, Leonard J. Appleman is currently recruiting for 4 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Leonard J. Appleman has studied deeply?
Yes, Leonard J. Appleman has studied treatments such as Abiraterone Acetate, Prednisone, Atezolizumab.
What is the best way to schedule an appointment with Leonard J. Appleman?
Apply for one of the trials that Leonard J. Appleman is conducting.
What is the office address of Leonard J. Appleman?
The office of Leonard J. Appleman is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.